ArticleBMC systems biology2016
Mathematical model on Alzheimer's disease.
Article in BMC systems biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 152 citations in OpenAlex.
- Data-driven modeling of spatiotemporal dynamics using multimodal imaging data.PLoS computational biology · 2026Article
- Microglia-driven neuroinflammatory signaling in neurodegeneration: mechanisms and therapeutic opportunities.Molecular biology reports · 2026Review
- Theory and simulations of delayed stochastic and deterministic models of prion diseases.Journal of mathematical biology · 2026Article
- Utilizing fractional-order operator to Alzheimer's disease dynamics.Scientific reports · 2026Article
- A Physics Informed Neural Network (PINN) framework for fractional order modeling of Alzheimer's disease.Frontiers in neuroinformatics · 2026Article
- A Mathematical Model for the Variation of Cerebral Electrical Conductivity and the Amount of β-Amyloid Protein Values Due to Alzheimer's Disease.Brain sciences · 2025Article
- Mathematical Modeling of Neuroinflammation in Neurodegenerative Diseases.CPT: pharmacometrics & systems pharmacology · 2025Review
- Data-driven modeling of amyloid-β targeted antibodies for Alzheimer's disease.NPJ systems biology and applications · 2025Article
- Article
- Monitoring and investigation to control the brain network disease under immunotherapy by using fractional operator.Scientific reports · 2025Article
- Optimal control of monomers and oligomers degradation in an Alzheimer's disease model.Journal of mathematical biology · 2025Article
- Stability and chaos analysis of neurological disorder of complex network with fractional order comparative study.Scientific reports · 2025Article
- Revealing Cortical Spreading Pathway of Neuropathological Events by Neural Optimal Mass Transport.IEEE transactions on medical imaging · 2025Article
- Sensitivity analysis of a mathematical model of Alzheimer's disease progression unveils important causal pathways.Frontiers in neuroinformatics · 2025Article
- The role of IPFrontiers in computational neuroscience · 2025Article
- Article
- Bifurcations in coupled amyloid-β aggregation-inflammation systems.NPJ systems biology and applications · 2024Article
- Roles of astrocytes and prions in Alzheimer's disease: insights from mathematical modeling.Journal of biological physics · 2024Article
- Data-driven Stochastic Model for Quantifying the Interplay Between Amyloid-beta and Calcium Levels in Alzheimer's Disease.Statistical analysis and data mining · 2024Article
- Pathology steered stratification network for subtype identification in Alzheimer's disease.Medical physics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer disease (AD) is a progressive neurodegenerative disease that destroys memory and cognitive skills. AD is characterized by the presence of two types of neuropathological hallmarks: extracellular plaques consisting of amyloid β-peptides and intracellular neurofibrillary tangles of hyperphosphorylated tau proteins. The disease affects 5 million people in the United States and 44 million world-wide. Currently there is no drug that can cure, stop or even slow the progression of the disease. If no cure is found, by 2050 the number of alzheimer's patients in the U.S. will reach 15 million and the cost of caring for them will exceed $ 1 trillion annually.
resultsThe present paper develops a mathematical model of AD that includes neurons, astrocytes, microglias and peripheral macrophages, as well as amyloid β aggregation and hyperphosphorylated tau proteins. The model is represented by a system of partial differential equations. The model is used to simulate the effect of drugs that either failed in clinical trials, or are currently in clinical trials.
conclusionsBased on these simulations it is suggested that combined therapy with TNF- α inhibitor and anti amyloid β could yield significant efficacy in slowing the progression of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.